We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Rating & price-target changes
Stored first · Google News · Yahoo Finance (English)
AVNS: What does Argus have to say about AVNS?
Avanos Medical (AVNS) Holds Steady Near Support – What Lies Ahead? - VWAP Bounce - DonanımHaber
Avanos Medical (AVNS) Holds Steady Near Support – What Lies Ahead? - VWAP Bounce DonanımHaber
Price to earnings forward of Avanos Medical, Inc. – MUN:8HH - TradingView
Price to earnings forward of Avanos Medical, Inc. – MUN:8HH TradingView
Latham Advises on Financing for American Industrial Partners’ US$1.272 Billion Acquisition of Avanos Medical, Inc. - Latham & Watkins LLP
Latham Advises on Financing for American Industrial Partners’ US$1.272 Billion Acquisition of Avanos Medical, Inc. Latham & Watkins LLP
Has Avanos Medical (AVNS) Run Ahead Of Fundamentals On Its Russell Index Removal? - simplywall.st
Has Avanos Medical (AVNS) Run Ahead Of Fundamentals On Its Russell Index Removal? simplywall.st
Avanos Medical (AVNS) Q4 2024 earnings summary - Quartr
Avanos Medical (AVNS) Q4 2024 earnings summary Quartr
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 05. | After market close (AMC) | $0.16 | — | — | $173M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.14 | — | — | $167.5M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $0.11 | — | — | $508.2M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $0.02 | — | — | $337.8M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2024. 05. 08. | JMP Securities | — | Maintain | — → Market Perform | — | JMP Securities: Market Perform |
| 2023. 07. 25. | Keybanc | — | Downgrade | Overweight → Sector Weight | — | Keybanc: Overweight → Sector Weight |
| 2023. 06. 21. | Stifel | — | Maintain | Hold → Hold | — | Stifel: Hold |
| 2023. 05. 22. | CL King | — | Initiate coverage | — → Buy | — | CL King: Buy |
| 2023. 05. 04. | Morgan Stanley | — | Maintain | — → Underweight | — | Morgan Stanley: Underweight |
| 2023. 02. 22. | Morgan Stanley | — | Maintain | — → Underweight | — | Morgan Stanley: Underweight |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.